PHILADELPHIA, PA--Context Therapeutics, a clinical stage biopharmaceutical company announced that it has acquired worldwide rights to Apristor.

Context Therapeutics, a University City firm set up to develop new cancerfighting drugs, has bought Apristor, the last drug owned by Arno Therapeutics, a Flemington, N.J., drug company that is dissolving.